表没食子儿茶素没食子酸酯对小鼠非酒精性脂肪肝的干预作用  

Effects of Epigallocatechin-3-gallate on Nonalcoholic Fatty Liver Disease in Mice

作　　者：沈晶[1] 舒恒 石孟琼[1] 张媛媛 朱丽金 雷乾坤 张继红[3,4] 贺海波 邹坤[2] SHEN Jing;SHU Heng;SHI Meng-qiong;ZHANG Yuan-yuan;ZHU Li-jin;LEI Qian-kun;ZHANG Ji-hong;HE Hai-bo;ZOU Kun(Medical Science College,China Three Gorges University,Yichang 443002,China;Hubei Key Laboratory of Natural Products Research and Development,China Three Gorges University,Yichang 443002,China;Chinese Medicine Clinical Medical College,China Three Gorges University,Yichang 443001,China;Yichang Key Laboratory of Development and Utilization Large Health Products with Medicine Food Homology,Yichang 443002,China)

机构地区：[1]三峡大学医学院,湖北宜昌443002 [2]三峡大学天然产物研究与利用湖北省重点实验室,湖北宜昌443002 [3]三峡大学中医临床医学院,湖北宜昌443001 [4]药食同源大健康产品开发利用宜昌市重点实验室,湖北宜昌443002

出　　处：《现代食品科技》2021年第4期33-43,71,共12页Modern Food Science and Technology

基　　金：宜昌市科学技术局资助项目(A18-302-a2);三峡大学硕士学位论文培优基金资助项目(2020SSPY114,2019SSPY159)。

摘　　要：本文研究了表没食子儿茶素没食子酸酯(EGCG)对小鼠非酒精性脂肪性肝病(NAFLD)的干预作用。应用高脂饲料喂养Apo E-/-小鼠建立NAFLD小鼠模型,研究EGCG对NAFLD小鼠血液和肝组织中糖脂代谢、脂肪酸氧化、氧化应激水平、肝组织结构以及AMPK/SIRT1/SREBP-1c/PPARγ信号通路相关基因表达的影响。结果表明EGCG治疗后肝组织病理学变化明显改善,小鼠体质量、肝质量、肝质量指数较模型组显著降低至110.98%、115.01%,115.64%、136.48%和104.20%、118.70%(p<0.01);血液和肝组织中糖脂代谢、脂肪酸氧化、氧化应激水平改善幅度在11.85%~86.06%之间,与模型组比较具有显著性差异(p<0.05或p<0.01);升高肝组织中AMPKα、SIRT1 mRNA及p-AMPKα、SIRT1蛋白表达幅度在13.21%~75.82%之间,降低肝组织FASN、ACC-1、SREBP-1c、SCD-1、PPARγm RNA和FASN、p-ACC-1、p-SREBP-1c、SCD-1、PPARγ蛋白表达幅度在19.59%~92.07%之间,改善p-AMPKα/AMPKα、p-ACC-1/ACC-1和p-SREBP-1c/SREBP-1c比率在39.20%~93.07%之间,与模型组比较具有显著性差异(p<0.05或p<0.01)。本研究表明EGCG可通过调控AMPK/SIRT1/SREBP-1c/PPARγ信号通路相关基因的表达来改善NAFLD小鼠糖脂代谢、脂肪酸氧化和氧化应激状态。The protective effects of epigallocatechin gallate(EGCG)on nonalcoholic fatty liver disease(NAFLD)in mice were investigated.The NAFLD Apo E-/-mice model was established by feeding high fat food.Then,the effects of EGCG on glucose and lipid metabolism,fatty acid oxidation,oxidative stress level,liver tissue structure and the gene expressions of AMPK/SIRT1/SREBP-1 c/PPARγsignaling pathway in NAFLD mice were analyzed.The results indicated that after EGCG treatment,the pathological changes of liver tissue were evidently ameliorated;compared with the model group,the body weight,liver mass and liver mass index of mice were significantly reduced to 110.98%,115.01%,115.64%,136.48%and 104.20%,118.70%respectively(p<0.01,respectively).The levels of glucose and lipid metabolism,fatty acid oxidation and oxidative stress in blood and liver tissues were markedly improved by 11.85%~86.06%compared with model group(p<0.05 or p<0.01,respectively).Further study indicated that the AMPKα,SIRT1 m RNA and p-AMPKα,SIRT1 protein expressions in liver tissue were obviously elevated by 13.21%~75.82%.In contrast,the FASN、ACC-1、SREBP-1 c、SCD-1、PPARγm RNA and FASN、p-ACC-1、p-SREBP-1 c、SCD-1、PPARγprotein expressions in liver tissue were dramatically reduced by 19.59%~92.07%,the p-AMPKα/AMPKα、p-ACC-1/ACC-1 and p-SREBP-1 c/SREBP-1 c ratios significantly ameliorated by 39.20%~93.07%compared with model group(p<0.05 or p<0.01,respectively).The results demonstrated that EGCG could ameliorate glucose and lipid metabolism,fatty acid oxidation and oxidative stress in NAFLD mice by regulating there lated gene expressions of AMPK/SIRT1/SREBP-1 c/PPARγsignaling pathway.

关 键 词：没食子儿茶素没食子酸酯 非酒精性脂肪性肝病 AMPK/SIRT1/SREBP-1c/PPARγ信号通路 

分 类 号：R285.5[医药卫生—中药学]